Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Cetirizine + cholecalciferol** is a non-standardized combination of two active substances: cetirizine, an oral second-generation antihistamine that acts mainly as a selective antagonist at the histamine H1 receptor, and cholecalciferol, also known as vitamin D3, a secosteroid hormone involved in calcium and phosphate homeostasis and bone metabolism. There is limited but emerging clinical evidence that the combination (administered as topical cetirizine plus oral cholecalciferol or both orally) can be used for conditions such as congenital hypotrichosis and allergic rhinitis, especially in patients with vitamin D deficiency[2][5][6].\n\nIn this combination:\n- **Cetirizine** blocks the action of endogenous histamine at the H1 receptor to prevent allergic symptoms such as itching, sneezing, and runny nose.\n- **Cholecalciferol (vitamin D3)** raises serum levels of vitamin D, potentially modulating immune response and inflammation.\n\nThere are no widely recognized proprietary combination products using both active ingredients under a single brand name, and both substances are most often co-administered in clinical practice based on specific therapeutic needs rather than as a fixed-dose combination.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cetirizine + cholecalciferol.